More power alley disclosures, now — as to by whom, and why-for — our Congress-critters are being wined and dined, in 2025.
We will likely add Lilly into the mix, by tomorrow night — but see the updated totals at right, and the deets… as to Amgen:
…Issues related to drug pricing; Issues related to cardiovascular disease awareness and treatment; Issues related to FDA; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Issues related to biosimilars reimbursement; Issues related to Supply Chain; Issues related to 340B; Issues related to pharmacy benefit managers; Issues related to biosimilars regulatory standards; Issues related to bone disease awareness and treatment; Issues related to Public law 117-1769 Inflation Reduction Act; Issues pertaining to the implementation of PL 97-414 “Orphan Drug Act,” all provisions; HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); S 1954 Biosimilar Red Tape Elimination Act; HR 5526 Biosimilar Red Tape Elimination Act; HR 2214 DRUG Act; H.R.1968 – Full-Year Continuing Appropriations and Extensions Act, 2025; HR 5509 Safe Step act; HR 5256 340B Access Act; HR 4581 340B Patients Act; S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act….
Issues related to drug pricing; Issues related to Public law 117-1769 Inflation Reduction Act; Issues related to cardiovascular disease awareness and treatment; Issues related to reimbursement for biologics/biosimilars; Issues related to PBM reform; Issues related to bone disease awareness and treatment; HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); H.R.1968 – Full-Year Continuing Appropriations and Extensions Act, 2025….
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14)….
Issues related to tariffs….
Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to patent thickets/product hopping; Issues related to obviousness / double patenting; Issues related to FDA/PTO coordination; Issues related to skinny labeling; S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; S.2296– NDAA (FY 2026 National Defense Authorization Act– BIOSECURE language); S 708/ HR 1574 — Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE); S.1553/HR3160– Promoting and Respecting Economically Viable American Innovation Act (PREVAIL); S. 1546/ HR 3152 — Patent Eligibility Restoration Act of 2025 (PERA)….
Now you know… “you have to break a few eggs, to make an. . . omelet.” And, separately, all solved on the La Guardia run, and music venue set-up is underway, for later tonight, at the House of Blues. Grin. Onward….
नमस्ते
Powerline Lies... 